Christina Annunziata

Christina Messineo Annunziata is an American medical oncologist researching molecular signal transduction in ovarian cancer. She is an investigator in the National Cancer Institute's women's malignancies branch and head of the translational genomics section.

Christina Annunziata
Alma materGeorgetown University Medical School (MD, PhD)
Scientific career
FieldsMedical oncology
InstitutionsNational Cancer Institute
ThesisCD40 signaling Hodgkin's disease (2000)

Education

Annunziata is a graduate of Georgetown University Medical School where she also completed graduate school and residency training in internal medicine.[1] Her dissertation was titled CD40 signaling Hodgkin's disease.[2]

She came to the National Cancer Institute (NCI) as a postdoctoral researcher for medical oncology training in the medical oncology branch. Annunziata joined the NCI laboratory of Louis M. Staudt in the metabolism branch to investigate NF-kappaB signaling in multiple myeloma. She returned to the medical oncology branch to extend her study of these molecular pathways in the ovarian cancer model.[1][3] She researched in the clinic of Elise C. Kohn.[4]

Career and research

Annunziata maintains her clinical focus in the translational clinical studies of ovarian cancer. She is an investigator and head of the NCI translational genomics section. She directs clinical operations for the women's malignancies branch. Annunziata holds board certification for the practice of medical oncology. Annunziata is a participating member in the Gynecologic Oncology Group, the American Association for Cancer Research, the American Society for Clinical Oncology, and the Society of Gynecologic Oncology. She serves as course director for the Women's Malignancies Lecture Series in the Women's Malignancies Branch, and Associate Editor for the international journal, BMC Cancer.[1]

gollark: Like I said, you could use osmarks.tk™ cloud™, we have more than *50%* uptime!
gollark: osmarks.tk™ cloud platform: No automation. No backups. At least it's cheap™™™.
gollark: Or use our managed service, where you send web applications to deploy.
gollark: Oh, right. Well, you could rent server time on the osmarks.tk™ cloud platform. We have over 50% uptime.
gollark: <@259973943060856833> If you rented a VM for Krist that would probably - without special configuration - only allow CPU mining. Which is too slow.

References
  1. "Christina M. Annunziata, M.D., Ph.D." Center for Cancer Research. 2014-08-12. Retrieved 2020-07-22. This article incorporates text from this source, which is in the public domain.
  2. Annunziata, Christina Messineo (2000). CD40 signaling Hodgkin's disease (Ph.D. thesis). Georgetown University. OCLC 45954730.
  3. "Principal Investigators". NIH Intramural Research Program. Retrieved 2020-07-22.
  4. "A Conversation with Christina Annunziata, M.D., Ph.D." Center for Cancer Research. 2020-06-25. Retrieved 2020-07-22. This article incorporates text from this source, which is in the public domain.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.